Decreased endomyocardial RANKL expression in transplant coronary artery disease

Transplantation

Volumn 81, Issue 10, 2006, Pages 1467-1470

  Ueland, Thor ^a   Gullestad, Lars ^a   Simonsen, Svein ^a   Endresen, Knut ^a   Scott, Helge ^a   Frøland, Stig S ^a   Geiran, Odd ^a   Fiane, Arnt E ^a   Aukrust, Pål ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coronary artery disease; Heart transplantation; RANKL

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTERY TRANSPLANTATION; ARTICLE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HEART MUSCLE BIOPSY; HUMAN; INFLAMMATION; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADOLESCENT; ADULT; CARRIER PROTEINS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYOCARDIUM; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TIME FACTORS; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 33744903128     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000209413.45179.f6     Document Type: Article

References (19)

1. Gallo P, Agozzino L, Angelini A, et al. Causes of late failure after heart transplantation: a ten-year survey. J Heart Lung Transplant 1997; 16: 1113.
2. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996; 93: 4051.
3. Ueland T, Sikkeland LI, Yndestad A, et al. Myocardial gene expression of inflammatory cytokines after heart transplantation in relation to the development of transplant coronary artery disease. Am J Cardiol 2003; 92: 715.
4. Cho HR, Kwon B, Yagita H, et al. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int 2004; 17: 351.
5. Ye Q, Fraser CC, Gao W, et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002; 195: 795.
6. Dhore CR, Cleutjens IP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998.
7. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303.
8. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024.
9. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1970.
10. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461.
11. Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334.
12. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685.
13. Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003; 32: 96.
14. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382.
15. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280: 334.
16. Kim HH, Shin HS, Kwak HJ, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. FASEB J 2003; 17: 2163.
17. Kageyama Y, Li XK, Suzuki S, et al. Apoptosis is involved in acute cardiac allograft rejection in rats. Ann Thorac Surg 1998; 65: 1604.
18. Laguens RP, Meckert PM, Martino JS, et al. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996; 15: 911.
19. Guillonneau C, Louvet C, Renaudin K, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 2004; 172: 1619.